Cerebral Venous Sinus Thrombosis induced By Hypercoagulation in Patient With Systemic Lupus Erythematosus: A Case Report and Literature Review

References

• Ahn GY, Kim D, Won S, et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus. 2018;27(8):1338–1347.
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum. 2007;36(5):297–315. doi:10.1016/j.semarthrit.2006.11.003
   PubMed Web of Science ®Google Scholar
• Yoshio T, Okamoto H, Hirohata S, Minota S. IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis Rheum. 2013;65(2):457–463. doi:10.1002/art.37745
   PubMedGoogle Scholar
• Duarte-Delgado NP, Vásquez G, Ortiz-Reyes BL. Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2019;18(4):426–432. doi:10.1016/j.autrev.2018.12.004
   PubMed Web of Science ®Google Scholar
• Horwitz H, Friis T, Modvig S, et al. Differential diagnoses to MS: experiences from an optic neuritis clinic. J Neurol. 2014;261:98–100.
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology. 2008;115:1079–82.e5.
   PubMed Web of Science ®Google Scholar
• Pérez Bartolomé F, García Vasco L, Abreu ventura N, et al. Diagnosis approach of optic neuritis. J Neurol Neurophysiol. 2015;6:345.
   Google Scholar
• Vollmer T, Signorovitch J, Huynh L, et al. The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis. J Neurol Sci. 2015;357(1–2):8–18.
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Multiple sclerosis review. P T. 2012;37(3):175–184.
   PubMedGoogle Scholar
• Yetimalar Y, Seçil Y, Inceoglu AK, et al. Unusual primary manifestations of multiple sclerosis. N Z Med J. 2008;121:47–59.
   PubMedGoogle Scholar
• Ergun U, Özer G, Şekercan S, et al. Headaches in the different phases of relapsing-remitting multiple sclerosis A tendency for stabbing headaches during relapses. Neurologist. 2009;15:212–216.
   PubMed Web of Science ®Google Scholar
• Gee JR, Chang J, Dublin AB, Vijayan N. The association of brainstem lesions with migraine- like headache: an imaging study of multiple sclerosis. Headache. 2005;45:670–677.
   PubMed Web of Science ®Google Scholar
• Elliott DG. Migraine in multiple sclerosis. Int Rev Neurobiol. 2007;79:281–302.
   PubMed Web of Science ®Google Scholar
• Appenzeller S, Costallat LT. Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage. Cephalalgia. 2004;24(12):1024–1030. doi:10.1111/j.1468-2982.2004.00785.x
   PubMed Web of Science ®Google Scholar
• Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. A Rev Immunol. 1992;10:153–187.
   PubMed Web of Science ®Google Scholar
• Bainbridge JL, Corboy JR, Gidal BE, et al. Multiple sclerosis. In: DiPiro JT, Talbert RL, Yee GC, editors. Pharmacotherapy: A Pathophysiological Approach, 5th. New York, NY: McGraw-Hill; 2002:1019–1030.
   Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis. Lancet Neurol. 2017. doi:10.1016/S1474-4422(17)30470-2
   Google Scholar
• Berkovich RR. Acute multiple sclerosis relapse. Continuum. 2016;22:799–814.
   PubMedGoogle Scholar
• Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84:1165–1173.
   PubMed Web of Science ®Google Scholar
• Aliaga ES. MRI mimics of multiple sclerosis. Handb Clin Neurol. 2014;122:291–316.
   PubMedGoogle Scholar
• Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;63(11):2028–2033.
   PubMed Web of Science ®Google Scholar
• Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev. 2008. doi:10.1002/14651858.CD006264
   PubMed Web of Science ®Google Scholar
• Costello K, Halper J, Kalb R, Skutnik L, Genzyme S, Rapp R The use of modifying drug therapy in multiple sclerosis. 2019.
   Google Scholar
• Yamout B, Sahraian M, Bohlega S, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord. 2020;37:101459.
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38:S26–S34.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann Intern Med. 2000;132:631–635.
   PubMed Web of Science ®Google Scholar
• Harrison DM, Gladstone DE, Hammond E, et al. of relapsing–remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Scler. 2012;18:202–209.
   PubMed Web of Science ®Google Scholar
• Michel L, Vukusic S, De Seze J, et al. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry. 2014;85:279–283.
   PubMed Web of Science ®Google Scholar
• Massacesi L, Tramacere I, Amoroso S, et al. Azathioprine versus beta interferons for relapsing–remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One. 2014;9:e113371.
   PubMed Web of Science ®Google Scholar
• Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23:905–912.
   PubMed Web of Science ®Google Scholar
• Amalia L. The role of platelet-selectin as a marker of thrombocyte aggregation on cerebral sinus venous thrombosis. J Blood Med. 2022;13:267–274.
   PubMed Web of Science ®Google Scholar